Up next

Senior Executives Highlight Mergers and Acquisitions and Expansions at DCAT Week ’18

At the DCAT Member Company Announcement Forum, held during DCAT Week, senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) provided the latest major news from their companies impacting the pharmaceutical manufacturing value chain. So what did they report?

The executives highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions. Lonza, DowDuPont, Catalent, Novasep, CordenPharma, Piramal Pharma Solutions, SK biotek, Biocon, Procos, Nosco, AB BioTechnologies, and PolyCrystalLine were among the companies taking the podium to provide their latest developments.

The executives highlighted developments to expand active pharmaceutical ingredient (API) development and manufacturing (both small molecules and biologics), drug-product development and manufacturing (both solid dosage and parenteral drugs), and packaging. A roundup of these developments are provided in the stories below.

Lonza Updates Integration of $5.5-Billion Acquisition of Capsugel

DowDuPont Outlines Integration of Combined Company, Including Excipients Business

Catalent Updates Integration of $950-Million Acquisition of Cook Pharmica

Novasep Announces $65-Million Investment in Biologics

CordenPharma Outlines Integration of Former Pfizer API Facility

Piramal Pharma Solutions CEO Outlines Expansion Plans

SK biotek Outlines Integration of Former BMS API Manufacturing Facility

Biocon COO Highlights Company’s Growth Strategy

Procos CEO Outlines Expansion for High-Potency Manufacturing

Nosco President Discusses Company’s Growth Strategy in Wake of Two Key Acquisitions

AB BioTechnologies CEO Announces $12-Million Expansion

PolyCrystalLine CEO Announces Expansion of Solid-State Chemistry Capabilities

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum

By
CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Capital expansions for small-molecule API manufacturing, including HPAPIs, biologics, and fill-finish topped the news.

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2026 Member Company News Roundup 

By
What other DCAT Member Companies are making news from DCAT Week? A roundup of the latest developments from suppliers and CDMOs/CMOs.

DCAT Week in Review: A Snapshot View of DCAT’s Education Programs

By
The education programs at DCAT Week 2026, held March 23–26, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the pharma customer–supplier relationship.

Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron

By
Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).